Preferred Label : Autologous Anti-glypican-3 CAR-IL-15-iC9-expressing T-lymphocytes;
NCIt synonyms : Autologous GPC3-specific CAR-IL-15-iCasp9 T Cells; Autologous Anti-GPC3-CAR-IL-15-iC9-expressing T-lymphocytes; Autologous iC9-IL-15-expressing AGAR T-cells; Autologous GPC3-CAR-IL-15-iC9-expressing T Cells; Autologous Anti-GPC3 CAR-IL-15-iCasp9-expressing T-lymphocytes;
NCIt definition : A preparation of T-lymphocytes that have been genetically modified to express a chimeric
antigen receptor (CAR) specific for glypican-3 (GPC3) and express interleukin-15 (IL-15)
and the suicide gene, inducible caspase 9 (iCasp9 or iC9), with potential immunostimulating
and antineoplastic activities. Upon administration, anti-GPC3-CAR-IL-15-iC9-expressing
T-lymphocytes specifically target and bind to GPC3-expressing tumor cells, resulting
in tumor cell lysis. GPC3, a heparan sulfate proteoglycan and a member of the glypican
family, is overexpressed on certain tumor cell types while minimally expressed on
normal, healthy cells; GPC3 plays an important role in cellular proliferation and
differentiation. IL-15 is a pro-survival cytokine that potentiates, in addition to
promoting T-cell proliferation and persistence, the immune response against tumor
cells. The iCasp9 safety switch consists of a full-length caspase 9, including its
caspase recruitment domain, linked to a human FK506 drug-binding domain with an F36V
mutation (FKBP12-F36V). If the administered CAR T-cells lead to unacceptable side
effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the
FKBP12-F36V drug-binding domain, activates caspase 9 and results in apoptosis of the
administered CAR T-cells.;
NCI Metathesaurus CUI : CL1773412;
Origin ID : C185176;
UMLS CUI : C5575456;
Semantic type(s)
- Cell [UMLS semantic type]
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
